The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Worldwide Exclusive Licensing Agreement for ResCu-SR(TM)

Thursday, April 26, 2012

Worldwide Exclusive Licensing Agreement for ResCu-SR(TM)09:00 EDT Thursday, April 26, 2012 Based on a Custom Product Formulation and Proprietary Delivery System SUDBURY, MA, April 26, 2012 /PRNewswire/ - Pure Encapsulations, Inc., the industry leader in manufacturing excellence and quality control, as well as a pioneer in the production of research-based and clinically relevant formulas to healthcare professionals, today announces an exclusive worldwide licensing agreement for ResCu-SRTM, a product developed in collaboration with Atrium Innovations, Maypro Industries LLC and Bioactives LLC. Recently launched, ResCu-SRTM offers a unique combination of highly bioavailable resveratrol and curcumin that are widely recognized approaches to longevity, inflammatory balance, cardioprotection and neurological health. Resveratrol and curcumin have been the subject of over 4,000 studies and are among the most extensively researched polyphenols. An emerging body of evidence also reveals that these two compounds work in synergy, meaning that the combination may be more effective at promoting health benefits than either agent alone. ResCu-SRTM was developed using a proprietary MicroActive® delivery technology from Bioactives that improves solubility, reduces particle size, improves absorption and provides a sustained release of the active compounds. The custom formulation was developed in collaboration with Maypro Industries and based on specifications elaborated by Atrium's Innovation Committee. "This collaborative product development initiative represents another example of our success in developing innovative products supported by extensive research," said Barry W. Ritz, Ph.D., Atrium Innovations' Vice President, Scientific and Regulatory Affairs. "We are proud to support via the Atrium Research Program our own product development, as well as the ongoing efforts of universities and medical institutions worldwide. These rigorous pursuits serve to identify the important role of dietary supplements in promoting human health," concluded Dr. Ritz. About Pure Encapsulations A subsidiary of Atrium Innovations Inc. [TSX: ATB], Pure EncapsulationsTM is committed to producing the most complete line of science-based nutritional supplements. Available exclusively through qualified health professionals, every finished product is formulated to best optimize the long-term health of the most sensitive patients.  Distributed worldwide, Pure EncapsulationsTM, products contain only the highest quality ingredients in their most bio-available forms and are formulated to provide strengths and dosing consistent with clinical experience and double-blind, placebo-controlled studies, the gold standard of research design. Pure EncapsulationsTM is an FDA-inspected facility and is NSF-GMP registered in the U.S., GMP certified in Canada and exceeds the standards of the United States Pharmacopeia (USP). Pure EncapsulationsTM is the choice of more than 36,000 health professionals in the U.S. and a leading brand in Europe. For more information, visit About Atrium Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements available mainly through healthcare practitioners and health food and specialized stores. Atrium supports active research ( and corporate social responsibility programs (  The Company has over 1,100 employees and operates eight manufacturing facilities. Additional information is available at SOURCE Pure Encapsulations, Inc.For further information: <p> <b>Joy Devins</b><br/> Vice President, Business Development<br/> Tel.: 978-443-1999<br/> <a href=""></a> </p>